Karyopharm Therapeutics has reached a significant milestone by completing patient enrolment for its Phase III SENTRY trial.

Revolution will now explore daraxonrasib’s potential as a monotherapy and in combination with chemotherapy in late-stage PDAC ...

In August, Regeneron announced positive results from Phase III clinical trial NIMBLE evaluating the efficacy and safety of ...

PhaseV has entered into a strategic partnership with Bioforum to enhance the efficiency of clinical trials using advanced ...

These readouts will help Regeneron structure the confirmatory trials for the two allergy combination therapies.

Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) ...

AstraZeneca's Tagrisso, in combination with pemetrexed and platinum-based chemotherapy, has shown a significant improvement ...

Takeda’s readout comes from two pivotal Phase III trials of its OX2R, with Alkermes’ data coming from a Phase II trial in NT1 ...

The editorial team covers all the latest drug and medical device news from this year’s ESC Congress. JuShoot via Shutterstock.com. Eyes in the pharma and medtech industries are directed to the ...

Maia Biotechnology’s telomerase modifier, ateganosine (THIO) demonstrated efficacy when given before Regeneron’s immune checkpoint inhibitor Libtayo (cemiplimab) during a Phase II trial in non-small ...

Paul Hingst, Prasun Mishra, and Naymisha Patel discussed risk management in clinical trials as a key measure to ensure supply and trial success. Credit: Athanasios Psimadis/ Arena International Events ...

Ascletis Pharma’s subcutaneous glucagon-like peptide 1 receptor agonist (GLP-1RA) ASC30 has demonstrated a half-life of 75 days when used as a maintenance therapy for obesity in a Phase Ib trial.